These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37850587)

  • 1. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
    Drillaud N; Cussac V; Bertho PO; Horvais V; Beurrier P; Ternisien C; Rose J; Fouassier M; Babuty A; Trossaërt M
    Transfusion; 2023 Dec; 63(12):2321-2327. PubMed ID: 37850587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
    Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
    Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
    Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
    Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
    Takedani H; Hirose J
    Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
    Nagao A; Deguchi A; Nogami K
    Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
    Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
    Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
    Boban A; Hermans C
    Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
    [No Abstract]   [Full Text] [Related]  

  • 13. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
    Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
    J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.
    John MJ; Chakrabarti P; Apte S; Bhattacharyya M; S C; Hansen T; Kolla R; Ross C; Seth T; Siddharthan N; Abraham A
    Res Pract Thromb Haemost; 2020 Nov; 4(8):1324-1330. PubMed ID: 33313471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
    Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
    Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A.
    Napolitano M; Nøhr AM
    Drugs R D; 2019 Dec; 19(4):381-390. PubMed ID: 31782067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.